Compare Nasdaq100 ETF (QQQ) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq100 ETF vs TG Therapeutics Inc — how do they compare? Nasdaq100 ETF trades at $751.19 (market cap $506.92B), while TG Therapeutics Inc trades at $55.14 (market cap $8.16B). The key difference: Nasdaq100 ETF is far larger — about 62.1× TG Therapeutics Inc's market cap, and Nasdaq100 ETF is more actively traded (48,326,518 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold Nasdaq100 ETF for 162 Days and TG Therapeutics Inc for 16 Days on average.
| QQQ | TGTX | |
|---|---|---|
Market Cap | $506.92B | $8.16B |
Volume | 48,326,518 | 1,735,121 |
52-Week High | $759.66 | $59.06 |
52-Week Low | $558.34 | $26.94 |
Typical Hold Time | 162 Days | 16 Days |
Sector | — | Health |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQ trades at $751.27, down 0.85% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional interest but faces mixed analyst sentiment with a 50% buy and 50% sell rating. Recent news highlights ongoing comparisons with lower-fee alternatives like QQQM and VOO, while AI-driven tech exposure remains a key growth driver amid market volatility concerns.
The outlook for QQQ hinges on tech sector performance and interest rate sensitivity. Opportunities include AI innovation and Nasdaq 100 leadership, but risks involve high concentration in tech stocks, valuation pressures, and macroeconomic headwinds. Investor sentiment is divided, reflecting the ETF's growth potential against fee competitiveness and market cyclicality.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nasdaq100 ETF
The ETF is designed to track the performance of the securities and the stocks in the NASDAQ-100 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on QQQ →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
